Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo
Sponsored by Denovo Biopharma LLC
About this trial
Last updated 4 years ago
Study ID
9777
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
Yes
Accepting
18 to 65 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 19 years ago
What is this trial about?
Assess the efficacy of a new drug (a receptor agonist that modulates the glutamatergic
activity) in the treatment of schizophrenia.
The primary objective of this study is to determine if a mGlu2/3 agonist dosed for 28
days is superior to placebo in the treatment of patients with schizophrenia as measured
by the Positive and Negative Symptom Scales (PANSS) total score.
What are the participation requirements?
Inclusion Criteria
- meet the DSM-IV criteria for schizophrenia as confirmed by modified SCID
Exclusion Criteria
- meet the full syndromal criteria for other Axis I disorder
- have taken any depot antipsychotic within 4 weeks before screening
- are taking mood-stabilizing agents